A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics

Abstract

Background Asthma in the elderly population has been focused because it affects quality of life and results in a higher hospitalization rate and mortality. Fluticasone furoate (FF)/vilanterole (VI) is a novel inhaled corticosteroids (ICS)/long-acting β2 agonist (LABA) combination being developed for once-daily administration for asthma with greater anti-inflammatory activity and longer duration of bronchidilation. The Ellipta^TM dry powder inhaler (DPI) has also been available as a new device with high levels of satisfaction and preference.

Methods A 12-week, randomized, open-label cross-over, pilot study was conducted in 18 elderly patients with bronchial asthma to compare the effectiveness of once-daily FF/VI 200/25 µg via the Ellipta^TM DPI vs. twice-daily fluticasone propionate (FP)/salmeterol (SAL) 500/50 µg via the Diskus^TM DPI. The study period included a 4-week run-in, the first 4-week treatment, and the second 4-week treatment. Respiratory functions, fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) scores were measured 0, 4, and 8 weeks after randomization. Preferences for their device were also assessed using a self-completed questionnaire.

Results Spirometric paramters, FeNO levels and ACT scores were not significantly different during the run-in period, the FP/SAL treatment period, and the FF/VI treatment period. FF/VI treatment via the Ellipta^TM DPI was preferred to the FP/SAL treatment via the Diskus^TM DPI (p<0.01).

Conclusions These data indicate that FF/VI treatment via the Ellipta^TM DPI is preferred in elderly patients with asthma based on its ease-of-use, suggesting the potential to improve patient adherence and, as a result, overall disease management.

• References

• 1 Haughney J, Aubier M, Jørgensen L. et al. Comparing asthma treatment in elderly versus younger patients. Respir Med 2011; 105: 838-845 doi:10.1016/j.rmed.2011.02.011 Epub 2011 Mar 23
• 2 Pite H, Pereira AM, Morais-Almeida M. et al. Prevalence of asthma and its association with rhinitis in the elderly. Respir Med 2014; 108: 1117-1126 doi:10.1016/j.rmed.2014.05.002 Epub 2014 May 14
• 3 Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010; 376: 803-813 doi:10.1016/S0140-6736(10)61087-2
• 4 Yáñez A, Cho SH, Soriano JB. et al. Asthma in the elderly: What we know and what we have yet to know. World Allergy Organ J 2014; 7: 8 doi:10.1186/1939-4551-7-8 eCollection 2014
• 5 Tsai CL, Lee WY, Hanania NA. et al. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol 2012; 129: 1252-1258.e1 doi:10.1016/j.jaci.2012.01.061 Epub 2012 Mar 3
• 6 Slavin RG, Haselkorn T, Lee JH. TENOR Study Group . et al. Asthma in older adults: Observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol 2006; 96: 406-414
• 7 Stupka E, deShazo R. Asthma in seniors: Part 1. Evidence for underdiagnosis, undertreatment, and increasing morbidity and mortality. Am J Med 2009; 122: 6-11 doi:10.1016/j.amjmed.2008.09.022
• 8 Jarjour NN, Erzurum SC, Bleecker ER. NHLBI Severe Asthma Research Program (SARP) . et al. Severe asthma: Lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012; 185: 356-362 doi:10.1164/rccm.201107-1317PP Epub 2011 Nov 17
• 9 Rossios C, To Y, To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011; 670: 244-251
• 10 Slack RJ, Barrett VJ, Morrison VS. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. Pharmacol Exp Ther 2011; 344: 218-230
• 11 Woodcock A, Bleecker ER, Lötvall J. et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest 2013; 144: 1222-1229
• 12 Ishiura Y, Fujimura M, Shiba Y. et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in Asthma-COPD overlap syndrome. Pulm Pharmacol Ther 2015; 35: 28-33 doi:10.1016/j.pupt.2015.10.005
• 13 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respi Dis 1987; 136: 225-244
• 14 Ishiura Y, Fujimura M, Yamamoto H. et al. COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. J Investig Allergol Clin Immunol 2009; 19: 370-374
• 15 Ishiura Y, Fujimura M, Yamamoto H. et al. Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome. Cough 2010; 6: 7
• 16 Oostveen E, MacLeod D, Lorino H. et al. ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003; 22: 1026-1041
• 17 Mori K, Shirai T, Mikamo M. et al. Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma. COPD 2011; 8: 456-463
• 18 Alving K, Janson C, Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res 2006; 7: 67
• 19 Nathan RA, Sorkness C, Kosinski M. et al. Development of the Asthma Control Test: A survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-63
• 20 Ishiura Y, Fujimura M, Yamamoto H. et al. Asthma exacerbations after the East Japan Disaster. J Med Invest 2013; 60: 61-65
• 21 Matza LS, Yu-Isenberg KS, Coyne KS. et al. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin 2008; 24: 3197-3206 doi:10.1185/03007990802463642 Epub 2008 Oct 14
• 22 Campbell MJ, Cogman GR, Holgate ST. et al. Age specific trends in asthma mortality in England and Wales, 1983-95: Results of an observational study. BMJ 1997; 314: 1439-1441
• 23 Hoskins G, McCowan C, Neville RG. et al. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19-24
• 24 Neville RG, Pearson MG, Richards N. et al A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J 1999; 14: 605-609
• 25 Horak F, Doberer D, Eber E. et al. Diagnosis and management of asthma – Statement on the 2015 GINA Guidelines. Wien Klin Wochenschr 2016; 128: 541-554 doi:10.1007/s00508-016-1019-4 Epub 2016 Jul 1
• 26 Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest 2001; 119: 720-725
• 27 Reed CE. Asthma in the elderly: Diagnosis and management. J Allergy Clin Immunol 2010; 126: 681-687 quiz 688-9 doi:10.1016/j.jaci.2010.05.035 Epub 2010 Jul 31
• 28 Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001; 17: 380-385
• 29 Bullens DM, Truyen E, Coteur L. et al. IL-17 mRNA in sputum of asthmatic patients: Linking T cell driven inflammation and granulocytic influx?. Respir Res 2006; 7: 135
• 30 Busse PJ, Mathur SK. Age-related changes in immune function: Effect on airway inflammation. J Allergy Clin Immunol 2010; 126: 690-699 quiz 700-1 doi:10.1016/j.jaci.2010.08.011
• 31 Brandenberger C, Li N, Jackson-Humbles DN. et al. Enhanced allergic airway disease in old mice is associated with a Th17 response. Clin Exp Allergy 2014; 44: 1282-1292 doi:10.1111/cea.12388
• 32 Ekici M, Apan A, Ekici A. et al. Perception of bronchoconstriction in elderly asthmatics. J Asthma 2001; 38: 691-696
• 33 Enright PL, McClelland RL, Newman AB. et al. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest 1999; 116: 603-613
• 34 Parameswaran K, Hildreth AJ, Chadha D. et al. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med 1998; 92: 573-577
• 35 Joyce DP, McIvor RA. Use of inhaled medications and urgent care services. Study of Canadian asthma patients. Can Fam Physician 1999; 45: 1707-1713
• 36 Gottlieb DJ, Beiser AS, O’Connor GT. Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston. Chest 1995; 108: 28-35
• 37 Williams LK, Pladevall M, Xi H. et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288-1293
• 38 Guyer AC, Long AA. Long-acting anticholinergics in the treatment of asthma. Curr Opin Allergy Clin Immunol 2013; 13: 392-398 doi:10.1097/ACI.0b013e328362a775
• 39 Wieshammer S. Dreyhaupt Dry powder inhalers: Which factors determine the frequency of handling erraors?. Respiration 2008; 75: 18-25
• 40 Melani AS, Bonavia M, Cilenti V. Gruppo educazionale associazione italiana pneumologi ospedalieri . et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930-938
• 41 Svedsater H, Dale P, Garrill K. et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013; 13: 72
• 42 Rossios C, To Y, To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011; 670: 244-251
• 43 Slack RJ, Barrett VJ, Morrison VS. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. Pharmacol Exp Ther 2011; 344: 218-230
• 44 Small M, Anderson P, Vickers A. et al. Importance of inhaler-device satisfaction in asthma treatment: Real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther 2011; 28: 202-212 doi:10.1007/s12325-010-0108-4 Epub 2011 Feb 10
• 45 Dransfield MT, Feldman G, Korenblat P. et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med 2014; 108: 1171-1179